AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a collaboration with VLST Corporation to generate novel multi-antigen specific antibody therapeutics for the treatment of autoimmune and inflammatory disorders. This is the fourth collaboration announced by AnaptysBio during 2010. Continue Reading
BioCision LLC today announced that it has agreed to a co-promotion program with Biohit Inc.. Biohit’s ErgoTube microcentrifuge tubes will now be branded and sold by both Biohit Inc. and BioCision. In addition, Biohit Inc. will cross-promote BioCision’s highly thermo-conductive CoolRack microfuge tube racks for use in combination with ErgoTubes. Continue Reading
The University of Illinois today announces that Chromatin, Inc., a biotechnology company that has occupied space in the University’s Research Park since 2005 as part of the EnterpriseWorks incubator, is expanding operations and graduating to a 5,000 square foot facility in the Research Park. The expansion marks the company’s continued significant progress in commercializing its proprietary technology, including mini-chromosomes which were originally developed at the University of Chicago by company co-founder and CEO Daphne Preuss. Continue Reading
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing. Continue Reading
Pluristem Therapeutics Inc. today announced that it has been granted a European Patent on its core 3D cell expansion technology. The granting of the European patent follows the issuance of several corresponding US patents as well as corresponding patents in ten additional jurisdictions. Continue Reading
BioTime, Inc. today reported financial results for the fourth quarter and fiscal year ended December 31, 2009 and provided an update on recent corporate developments. Continue Reading
Feintuch Communications, Inc. (www.feintuchcommunications.com) has created an integrated public and investor relations healthcare and life sciences practice, naming Jules Abraham as vice president of the firm and managing director of the new group. Continue Reading
Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott’s early- and mid-stage pharmaceutical pipeline. Continue Reading
InterMune, Inc. announced today that the U.S. Food and Drug Administration’s Pulmonary-Allergy Drugs Advisory Committee voted 9-3 to recommend approval of Esbriet® (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function. Continue Reading
Pharmaceutical companies could substantially reduce the expense of costly treatments for cancer and other diseases produced from mammalian or bacterial cells by growing these human therapeutic proteins in algae-rapidly growing aquatic plant cells that have recently gained attention for their ability to produce biofuels. Continue Reading
